Get the Stockscreener App
407.54
0.06%
-0.25
Vertex Pharmaceuticals Inc stock is traded at $407.54, with a volume of 393.11K.
It is down -0.06% in the last 24 hours and up +3.29% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$407.79
Open:
$404.21
24h Volume:
393.11K
Relative Volume:
0.22
Market Cap:
$104.51B
Revenue:
$11.39B
Net Income/Loss:
$3.64B
P/E Ratio:
29.13
EPS:
13.9904
Net Cash Flow:
$3.50B
1W Performance:
+1.15%
1M Performance:
+3.29%
6M Performance:
-15.84%
1Y Performance:
-15.40%
1-Day Range:
$402.58
$409.47
1-Week Range:
$400.86
$422.73
52-Week Range:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.99 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.71 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Griffin Asset Management Inc. Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsProfit Target & Weekly Market Pulse Alerts - newser.com
Promising Biotech Stocks To Follow NowOctober 11th - MarketBeat
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potentialJuly 2025 Technicals & AI Powered Buy/Sell Recommendations - newser.com
Apollon Wealth Management LLC Purchases 4,630 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Meritage Portfolio Management Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Vanguard Personalized Indexing Management LLC - MarketBeat
US Bancorp DE Acquires 1,324 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Commerzbank Aktiengesellschaft FI Has $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Galvin Gaustad & Stein LLC - MarketBeat
Aberdeen Group plc Has $128.20 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Callan Family Office LLC - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Blair William & Co. IL - MarketBeat
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News - GuruFocus
Pharma Compliance Trends Revealed at PCC West - BioXconomy
Recovering from injury, Boston Celtics star Jayson Tatum laces up for Vertex campaign - PRWeek
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Quantitative breakdown of Vertex Pharmaceuticals Incorporated recent moveWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Vertex Pharmaceuticals Incorporated stock daily chart insightsJuly 2025 Setups & Risk Managed Investment Signals - newser.com
Trifecta Capital Advisors LLC Buys 802 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Optas LLC Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vontobel Holding Ltd. Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Weiss Ratings Reiterates "Hold (C+)" Rating for Vertex Pharmaceuticals (NASDAQ:VRTX) - MarketBeat
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market - Nasdaq
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Indicators - Markets Mojo
Is Vertex Stock Poised for Growth After Positive CRISPR Therapy Trial Results in 2025? - Yahoo Finance
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors - Business Wire
Prime Capital Investment Advisors LLC Cuts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Best Biotech Stocks To Follow NowOctober 6th - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $530.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Motley Fool
Vertex’s quest for a breakthrough in Type 1 diabetes - Pharma Voice
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
RBC Raises Price Target on Vertex Pharmaceuticals to $423 From $405, Keeps Sector Perform Rating - MarketScreener
Dohj LLC Purchases Shares of 857 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Smartest Growth Stock to Buy With $500 Right Now - Yahoo Finance
The 5 Most Powerful Women in Biopharma - BioSpace
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Stake Lifted by KLP Kapitalforvaltning AS - MarketBeat
Shell Asset Management Co. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
SteelPeak Wealth LLC Makes New $10.06 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Simplicity Wealth LLC Purchases 1,736 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals a Smart Investment After Recent FDA Approval for Sickle Cell Therapy? - Sahm
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd - Business Wire
Former Vertex COO named chief executive at Dravet-focused biotech - The Business Journals
What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet? - Yahoo Finance
Vertex Pharmaceuticals: Strong Growth Potential with Promising Product Launches and Robust Pipeline - TipRanks
Cullinan Associates Inc. Sells 1,100 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Will Vertex Pharmaceuticals Incorporated price bounce be sustainableJuly 2025 Momentum & AI Enhanced Execution Alerts - newser.com
Published on: 2025-10-06 04:49:48 - newser.com
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.88%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):